The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://my-social-box.com/story6167902/retatrutide-vs-tirzepatide-a-comparative-analysis